Exelixis Inc
NASDAQ:EXEL
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
20.17
36.25
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Exelixis Inc
Exelixis Inc
Revenue
Exelixis Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Exelixis Inc
NASDAQ:EXEL
|
Revenue
$2.1B
|
CAGR 3-Years
18%
|
CAGR 5-Years
17%
|
CAGR 10-Years
58%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$55.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$28.3B
|
CAGR 3-Years
1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$32.5B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$10.6B
|
CAGR 3-Years
14%
|
CAGR 5-Years
24%
|
CAGR 10-Years
30%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.8B
|
CAGR 3-Years
1%
|
CAGR 5-Years
16%
|
CAGR 10-Years
18%
|
|
Exelixis Inc
Revenue Breakdown
Breakdown by Geography
Exelixis Inc
|
Total Revenue:
1.8B
USD
|
|
United States:
1.6B
USD
|
|
Europe:
145m
USD
|
|
Japan:
39.5m
USD
|
Breakdown by Segments
Exelixis Inc
Exelixis Inc
Glance View
Exelixis Inc., a prominent player in the biotech landscape, is dedicated to advancing cancer treatment through its innovative drug development programs. Founded in 1994 and based in South San Francisco, the company made its mark with cabozantinib, a multi-kinase inhibitor that targets key pathways involved in tumor growth, particularly in advanced kidney and liver cancers. Since its initial approval in 2012, cabozantinib has not only become a cornerstone of Exelixis's product portfolio but has also garnered recognition for improving patient outcomes where traditional therapies have fallen short. This success has positioned Exelixis as a leader in precision medicine, with a robust pipeline that includes additional therapies currently undergoing clinical trials, aimed at expanding treatment options for various cancer types. For investors, Exelixis offers an appealing blend of established market presence and promising growth potential. The company's strategic focus on maximizing cabozantinib’s sales while developing complementary therapies ensures a sustainable revenue stream, which is further supported by collaborations with major pharmaceutical partners. As the company continues to explore new indications and combinations, it signals a commitment to innovation that could enhance shareholder value. Moreover, Exelixis operates in a rapidly evolving market characterized by increasing demand for targeted cancer therapies, positioning itself well to capitalize on future opportunities. With a solid foundation and a forward-looking approach, Exelixis Inc. stands out as a compelling investment choice for those looking to participate in the biotech sector's growth.
See Also
What is Exelixis Inc's Revenue?
Revenue
2.1B
USD
Based on the financial report for Sep 30, 2024, Exelixis Inc's Revenue amounts to 2.1B USD.
What is Exelixis Inc's Revenue growth rate?
Revenue CAGR 10Y
58%
Over the last year, the Revenue growth was 17%. The average annual Revenue growth rates for Exelixis Inc have been 18% over the past three years , 17% over the past five years , and 58% over the past ten years .
You don't have any saved screeners yet
